Ejso最新文献

{"title":"What are the outcomes for long-term survivors after esophagectomy ? – Evidence from a randomized controlled trial (FFCD9901)","authors":"William B. Robb ,&nbsp;Julie Veziant ,&nbsp;Laetitia Dahan ,&nbsp;Françoise Mornex ,&nbsp;Emilie Barbier ,&nbsp;Xavier Benoît D'Journo ,&nbsp;Sylvain Manfredi ,&nbsp;Valérie Boige ,&nbsp;Marine Jary ,&nbsp;Niki Christou ,&nbsp;Côme Lepage ,&nbsp;Guillaume Piessen","doi":"10.1016/j.ejso.2025.109736","DOIUrl":"10.1016/j.ejso.2025.109736","url":null,"abstract":"<div><h3>Background</h3><div>Little is known regarding long-term outcomes of survivors beyond 5 years after esophagectomy. This study assesses oncological outcomes of long-term survivors of esophageal cancer.</div></div><div><h3>Methods</h3><div>Data is derived from a multi-center randomized controlled trial comparing neoadjuvant chemoradiotherapy (NCRT) and surgery to surgery alone for clinically stage I and II esophageal cancers (FFCD9901). Only patients undergoing esophagectomy were included in this study. Clinicopathological variables of 5-year survivors were analyzed. Multivariate logistic regression analysis identified factors predictive of death prior to 5 years. Patterns of disease recurrence and second primary tumor development were established.</div></div><div><h3>Results</h3><div>From June 2000 until June 2009, 195 patients from 30 French centers were randomly assigned to NCRT followed by surgery or surgery alone. Of 170 patients who underwent esophagectomy, 70 patients were alive at 5 years - an overall 5-year survival of 41.2 %. In logistic regression multivariate analysis, WHO performance status of ≥1 (p = 0.045), advanced pT category (p = 0.030) and post-operative complications (p = 0.047) predicted death prior to 5 years. Twenty patients died after the 5-year time point, 9 of these due to progression of their esophageal cancer. Nineteen patients developed a second primary malignancy, of whom 14 developed either a head and neck or lung cancers.</div></div><div><h3>Conclusions</h3><div>Being alive 5 years after esophagectomy does not equate to cure. In clinically staged early disease, a distinct group of patients develop disease recurrence later than 5 years from treatment. Development of a second primary cancer in this population poses a clinical threat. Surveillance protocols should be adapted accordingly.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109736"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143684377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is total mesorectal excision mandatory in advanced ovarian cancer patients undergoing posterior pelvic exenteration? Prognostic role of mesorectal space involvement in a prospective ovarian cancer cohort","authors":"Domenico Ferraioli ,&nbsp;Luca Fuso ,&nbsp;Francesca Chiadó ,&nbsp;Chiara Russo ,&nbsp;Lea Rossi ,&nbsp;Fulvio Borella ,&nbsp;Olivia Le Saux ,&nbsp;Isabelle Ray-Coquard ,&nbsp;Pierre Meeus ,&nbsp;Nicolas Chopin","doi":"10.1016/j.ejso.2025.109749","DOIUrl":"10.1016/j.ejso.2025.109749","url":null,"abstract":"<div><h3>Introduction</h3><div>In advanced epithelial ovarian cancer (AEOC), debulking surgery with posterior pelvic exenteration (PPE) is performed in 35–70 % of the patients to achieve no macroscopic residual disease.</div><div>This study aims to evaluate the incidence of mesorectal involvement and its prognostic role in AEOC patients undergoing PPE.</div></div><div><h3>Materials and methods</h3><div>This prospective study analyzes data from a cohort of AEOC patients who underwent primary debulking surgery (PDS) or interval debulking surgery (IDS) with PPE at the Léon Bérard Cancer Center in Lyon between 2018 and 2022.</div></div><div><h3>Results</h3><div>73 patients underwent debulking surgery with PPE during the study period.</div><div>27 (34 %) underwent PPE during PDS and 46 (66 %) during IDS. 23 patients (31.5 %) had only serosal involvement, 19 (26 %) had bowel involvement up to the muscularis propria, and 7 (9.6 %) had up to the mucosa. Mesorectal involvement was observed in 40 cases (54.7 %) and was significantly associated with positive MLNs and higher liver recurrence rates. Hepatic metastases had an early onset (months, 9.8 vs 28.8; p = 0.0001) and were correlated with poorer OS (months, 20.9 vs 51.5) compared to recurrences in other sites.</div><div>The persistence of positive mesorectum after neoadjuvant chemotherapy in the IDS group seemed to be linked to poor OS (NR vs 42.7 months).</div></div><div><h3>Conclusions</h3><div>Debulking surgery with PPE in AEOC patients is often needed. Total mesorectal excision should be performed in AEOC to achieve no residual disease because positive mesorectum after neoadjuvant chemotherapy seemed to be linked with poor OS, with early onset and increased incidence of liver metastasis.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109749"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the efficacy and safety of combined surgery with intraoperative radiotherapy and postoperative PVC for hepatocellular carcinoma with mPVTT","authors":"Zebing Song ,&nbsp;Hang Li ,&nbsp;Hailong Chen ,&nbsp;Bingqing Du ,&nbsp;Zongbing Cheng ,&nbsp;Zengyi Mo,&nbsp;Zejun Huang,&nbsp;Sihan Hu,&nbsp;Yujian Feng,&nbsp;Wujian Deng,&nbsp;Huihong Liang,&nbsp;Xuewei Yang,&nbsp;Xiaodong Song,&nbsp;Zili Shao","doi":"10.1016/j.ejso.2025.109727","DOIUrl":"10.1016/j.ejso.2025.109727","url":null,"abstract":"<div><h3>Background</h3><div>Hepatocellular carcinoma (HCC) accompanied by main portal vein tumor thrombosis (mPVTT) is associated with poor prognosis and limited treatment options. This study aimed to evaluate the efficacy and safety of a novel triple therapy approach combining surgery, intraoperative radiotherapy (IORT), and postoperative portal vein infusion chemotherapy (PVC) for HCC with mPVTT.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on 56 patients diagnosed with HCC and mPVTT. Patients were divided into two groups: the surgery-IORT-PVC group (n = 21) and the transcatheter arterial chemoembolization (TACE) combined with hepatic arterial infusion chemotherapy (HAIC) group (n = 35). Baseline characteristics, treatment procedures, postoperative complications, and survival outcomes were compared between the two groups.</div></div><div><h3>Results</h3><div>The surgery-IORT-PVC group (n = 21) demonstrated superior median overall survival (OS) (not reached vs. 7 months, <em>P</em> &lt; 0.05 4.99(2.543–9.792)) and median progression-free survival (PFS) (not reached vs. 4 months, <em>P</em> &lt; 0.05 5.268(2.765–10.03)) compared to the TACE-HAIC group (n = 35). Additional, the 1-year, 2-year, and 3-year OS (75.6 %, 60.5 %, 60.5 % vs 28.8 %, 8.2 %, 8.2 %) and PFS (73.3 %, 64.1 %, 64.1 % vs 9.5 %, 9.5 %, 9.5 %) of the surgery-IORT-PVC group significantly superior to that of the TACE-HAIC group. Multivariate analysis identified the treatment modality as an independent factor influencing both OS and PFS. Postoperative complications in the surgery-IORT-PVC group were manageable. No severe adverse events were reported in either group.</div></div><div><h3>Conclusion</h3><div>Overall, this novel treatment modality offers a potential effective therapy modality for patients with HCC and mPVTT who previously had limited therapeutic options.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109727"},"PeriodicalIF":3.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Complex segmentectomies: Comparison with simple and effect of experience on postoperative outcomes”","authors":"Carlos Galvez ,&nbsp;Sergio Bolufer ,&nbsp;Francisco Lirio ,&nbsp;Jose Luis Recuero ,&nbsp;Juan Manuel Córcoles ,&nbsp;Laura Socci ,&nbsp;Alberto Cabañero ,&nbsp;Iker López ,&nbsp;David Sánchez ,&nbsp;Santiago Figueroa ,&nbsp;José García Salcedo ,&nbsp;José Luis Campo-Cañaveral ,&nbsp;Marta Genovés ,&nbsp;Florentino Hernando ,&nbsp;Milagros Moldes ,&nbsp;Ana Blanco ,&nbsp;Leire Azcarate ,&nbsp;Eduardo Rivo ,&nbsp;Andrea Viti ,&nbsp;Roberto Mongil","doi":"10.1016/j.ejso.2025.109748","DOIUrl":"10.1016/j.ejso.2025.109748","url":null,"abstract":"<div><h3>Objectives</h3><div>We compared simple and complex segmentectomies in terms of complications and mortality. We hypothesized which proportion of complex segmentectomies might improve postoperative outcomes.</div></div><div><h3>Methods</h3><div>Patients from 18 hospitals operated since september 2018 to December 2019 were prospectively collected. Primary peripheral lung cancer or peripheral solitary nodules ≤2 cm, lung metastasis, carcinoids and benign lesions not amenable to wedge resection were included. Patients less than 18 years old, compromised patients, middle lobe lesions, preoperative induction or adjuvant treatment and patients without follow-up were excluded.</div></div><div><h3>Results</h3><div>261 (72.5 %) and 99 (27.5 %) were simple and complex segmentectomies. Median operative time was 146.5 min being slightly higher in complex segmentectomies (p = 0.05) while mean chest tube duration was 1 day, higher in simple than in complex (p = 0.01). 102 patients presented complications (28 %), with pulmonary complications accounting 21 %, prolonged air leak (PAL) 9.7 % and pneumonia 8.3 % as the most common. Postoperative pneumonia was 3.4-fold higher in the simple segmentectomy group (p = 0.02) and the combined respiratory morbidity almost doubled that of the complex (p = 0.02). After propensity-score matching, only operative time was shorter in the simple group (p = 0.02). Centers performing at least 40 % complex segmentectomies, presented significantly lower rate of PAL and pulmonary complications.</div></div><div><h3>Conclusions</h3><div>Complex segmentectomies are safe but longer procedures compared to simple and there is no risk of higher rate of operative or postoperative complications. Centers experienced in complex segmentectomies accomplishing at least 40 % from the total, present better outcomes in terms of prolonged air leak and pulmonary complications.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109748"},"PeriodicalIF":3.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143580650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous undifferentiated pleomorphic sarcoma is more aggressive than pleomorphic dermal sarcoma: Prognosis from a Danish nationwide registry-based cohort","authors":"Mathias Ørholt ,&nbsp;Ida Wulff ,&nbsp;Kiya Abebe ,&nbsp;Tim K. Weltz ,&nbsp;Mathilde N. Hemmingsen ,&nbsp;Anne L. Wagenblast ,&nbsp;Grethe Schmidt ,&nbsp;David H. Jensen ,&nbsp;Michael M. Petersen ,&nbsp;Anand C. Loya ,&nbsp;Søren Daugaard ,&nbsp;Thomas Mentzel ,&nbsp;Mikkel Herly ,&nbsp;Peter Vester-Glowinski","doi":"10.1016/j.ejso.2025.109747","DOIUrl":"10.1016/j.ejso.2025.109747","url":null,"abstract":"<div><h3>Introduction</h3><div>Subcutaneous undifferentiated pleomorphic sarcoma (scUPS) has not previously been described separately from pleomorphic dermal sarcoma (PDS), and consequently the prognosis for patients with scUPS is unknown.</div></div><div><h3>Materials and methods</h3><div>In this nationwide cohort study, we identified all patients in Denmark diagnosed with scUPS or PDS between 2002 and 2022. The outcomes were 5-year local recurrence, loco-regional and distant metastasis, and overall survival.</div></div><div><h3>Results</h3><div>We included 271 patients, 131 with scUPS and 140 with PDS. Patients with scUPS exhibited higher 5-year risks than patients with PDS in terms of the overall risk of metastasis (19 % vs. 7 %, p = 0.006) and distant metastasis only (12 % vs. 2 %, p = 0.004). The 5-year overall survival for patients with scUPS was 50 %, compared to 67 % for patients with PDS (p = 0.004).</div></div><div><h3>Conclusion</h3><div>Our findings indicate that patients with scUPS have a significantly worse prognosis than patients with PDS, with a higher overall risk of metastasis and a prolonged metastatic risk. This suggests a more extended follow-up program focusing on the detection of distant metastasis for patients with scUPS, whereas the follow-up of patients with PDS can be limited to clinical controls.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109747"},"PeriodicalIF":3.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143580648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A prevalence meta-analysis","authors":"Omar Mahmud ,&nbsp;Asad Saulat Fatimi ,&nbsp;Mahip Grewal ,&nbsp;Charles DiMaggio ,&nbsp;D. Brock Hewitt ,&nbsp;Ammar A. Javed ,&nbsp;Christopher L. Wolfgang ,&nbsp;Greg D. Sacks","doi":"10.1016/j.ejso.2025.109742","DOIUrl":"10.1016/j.ejso.2025.109742","url":null,"abstract":"<div><h3>Background</h3><div>Current guidelines recommend the resection of main duct- (MD) and mixed-type (MT) intraductal papillary mucinous neoplasms (IPMN) based on specific risk criteria to prevent or treat pancreatic cancer in selected patients. This paradigm follows high rates of malignancy observed in published surgical series. The aim of this systematic review and meta-analysis was to provide robust, pooled rates of invasive carcinoma (IC) and high-grade dysplasia (HGD) in resected MD- and MT-IPMNs of the pancreas.</div></div><div><h3>Methods</h3><div>The PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL databases were systematically searched. Studies that reported rates of IC or HGD, diagnosed by histopathology of surgical specimens, in MD- or MT-IPMNs were included. Pooled prevalence with 95 % confidence interval (95 % CI) was calculated using a random effects model. Galbraith plots were used to evaluate heterogeneity. Risk of bias was assessed using the National Institutes of Health Quality Assessment Tool.</div></div><div><h3>Results</h3><div>Based on 51 studies, 59 % (95 % CI: 54 %, 64 %) of resected MD- and MT-IPMN had IC or HGD, with IC in up to 39 % (95 % CI: 33 %, 44 %) of lesions and HGD in 20 % (95 % CI: 16 %, 25 %). Most studies were deemed to be of good quality and Galbraith plots demonstrated high concordance.</div></div><div><h3>Conclusions</h3><div>These results confirm the rates of IC and HGD in resected MD/MT-IPMNs. However, a significant proportion of patients have benign lesions, and future research is needed to develop precise diagnostics to distinguish between patients with and without high-risk or cancerous disease.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109742"},"PeriodicalIF":3.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Evaluating the feasibility of repeat sentinel lymph node biopsy in ipsilateral breast tumor recurrence: Technical considerations and oncologic outcomes”","authors":"Mingjuan Xu ,&nbsp;Xiaocun Zhu ,&nbsp;Juan Zhu ,&nbsp;Linlin Zhen","doi":"10.1016/j.ejso.2025.109741","DOIUrl":"10.1016/j.ejso.2025.109741","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109741"},"PeriodicalIF":3.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P16/HPV-negative oropharyngeal squamous cell carcinoma survival: Comparing primary surgery to primary chemoradiotherapy. A systematic review and meta-analysis","authors":"Bianca Maria Festa ,&nbsp;Nancy Schaefer ,&nbsp;William Reschly ,&nbsp;William M. Mendenhall ,&nbsp;Dustin Conrad ,&nbsp;Krishna Hanubal ,&nbsp;Mohamed Shama ,&nbsp;Carolyn O. Dirain ,&nbsp;Brian Hughley ,&nbsp;Deepa Danan ,&nbsp;Peter T. Dziegielewski","doi":"10.1016/j.ejso.2025.109739","DOIUrl":"10.1016/j.ejso.2025.109739","url":null,"abstract":"<div><h3>Objectives</h3><div>This study investigated differences in survival for p16/HPV-negative OPSCC patients treated with primary surgery versus primary (chemo-)radiation therapy (CRT).</div></div><div><h3>Materials and methods</h3><div>PubMed, CINAHL and Web of Science databases and the online Cochrane Library were searched for relevant English language studies describing the survival outcomes of p16/HPV-negative OPSCC patients treated with primary surgery or primary CRT. The primary endpoint was the 5-year OS; the secondary endpoints included 5-year DSS and DFS, and 3- and 2-year OS, DSS and DFS. The pooled survival curves were estimated using a distribution-free approach assuming random effects. Cumulative KM curves for OS, DSS and DFS were built for each treatment group.</div></div><div><h3>Results</h3><div>Twenty-two publications were included in the final analysis. Patients included (n = 1903) were divided according to treatment (“surgery” group, n = 942; “RT/CRT” group, n = 961). For all the endpoints, surgery demonstrated improved short- and long-term survival compared to RT/CRT, although selection bias may have impacted the outcomes. The estimated pooled 5-year OS for the surgery and the RT/CRT group was 54.1 % (95 % CI: 44.4%–65.9 %) and 45.7 % (95 % CI: 41.8%–49.9 %), respectively.</div></div><div><h3>Conclusion</h3><div>Primary surgery and primary CRT for p16/HPV-negative OPSCC both provide acceptable survival outcomes, although in many cases surgery has shown improved survival rates. Further research should focus on when each treatment modality should be used to achieve the goals of treatment completion, survival and functional outcomes.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109739"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143637433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes following inferior vena cava reconstruction at an advanced surgical unit","authors":"Evonne Z. Younan ,&nbsp;Charles W.G. Risbey ,&nbsp;Lylee Ye ,&nbsp;Sascha Karunaratne ,&nbsp;Doruk Seyfi ,&nbsp;Daniel Steffens ,&nbsp;Peter J. Lee ,&nbsp;Jerome Laurence ,&nbsp;Charbel Sandroussi","doi":"10.1016/j.ejso.2025.109740","DOIUrl":"10.1016/j.ejso.2025.109740","url":null,"abstract":"<div><h3>Background</h3><div>Inferior vena cava (IVC) resection and reconstruction is a viable option for managing complex intra-abdominal tumours. This study evaluates the impact of surgical approach to IVC reconstruction on early oncological, post-operative and short-term survival outcomes.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included patients who underwent IVC reconstruction between January 2015 and June 2024 for any indication, at two tertiary referral hospitals in Sydney, Australia. Data extracted included demographics, anticoagulation, histopathological findings, post-operative complications and short-term survival. Outcomes were compared among patients who received an interposition graft, patch graft or primary repair (non-graft) using nonparametric statistical tests.</div></div><div><h3>Results</h3><div>Seventy-one IVC reconstructions were performed with median age 59 years (IQR 48–69). A bovine pericardium (BP) graft was used in 86% of procedures (n=61). The most common indications for surgery were soft tissue sarcoma (n=17) and renal cell carcinoma (n=16). Post-operatively, there were seven cases of pulmonary embolism (PE), nine cases of graft thrombosis and one case of graft infection. 30-day survival was 99% and 12-month survival was 78%. Tumour size was greater in the interposition graft group (p=0.004), however no differences in post-operative complications or survival were observed between interposition graft, patch graft or primary repairs.</div></div><div><h3>Conclusions</h3><div>IVC reconstruction, particularly using BP, is feasible across a range of tumour types and offers favourable post-operative and short-term survival outcomes, independent of reconstruction technique. BP interposition graft facilitates resection of more extensive disease with similar outcomes to less extensive disease managed with primary repair or patch graft.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109740"},"PeriodicalIF":3.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of fluorescent lymphography-guided lymph node dissection during minimally invasive gastrectomy following chemotherapy","authors":"Ji Yoon Jeong ,&nbsp;Ja Kyung Yoon ,&nbsp;Jawon Hwang ,&nbsp;Sung Hyun Park ,&nbsp;Minah Cho ,&nbsp;Yoo Min Kim ,&nbsp;Hyoung-Il Kim ,&nbsp;Hyunki Kim ,&nbsp;Woo Jin Hyung","doi":"10.1016/j.ejso.2025.109738","DOIUrl":"10.1016/j.ejso.2025.109738","url":null,"abstract":"<div><h3>Introduction</h3><div>Fluorescent lymphography-guided lymph node dissection (FL) using indocyanine green (ICG) during radical gastrectomy for gastric cancer has shown enhanced lymph node (LN) retrieval and high sensitivity in detecting LN metastases. However, the impact of FL during gastrectomy following chemotherapy remains uncertain because changes in the ICG injection site due to tumor shrinkage may potentially visualize different lymphatic drainage from the tumor. This study aimed to assess the diagnostic performance of FL during gastrectomy after preoperative chemotherapy.</div></div><div><h3>Materials and Methods</h3><div>This retrospective study included patients who underwent minimally invasive gastrectomy with FL following chemotherapy between January 2013 and February 2024. Patients were categorized according to their tumor response after chemotherapy based on endoscopic, radiologic, and pathological findings.</div></div><div><h3>Results</h3><div>Of 29 patients, 9.4 (range 8–12) LN stations containing 6.9 (range 3–11) fluorescent LN stations, which had 56.3 (range 33–99) LNs including 33.4 (range 11–68) fluorescent LNs, were retrieved per patient. While 52 metastatic LN stations were fluorescent, three non-fluorescent metastatic LN stations were identified in one patient (3.4 %). FL showed 94.5 % (52/55) sensitivity and 95.9 % (70/73) negative predictive value for detecting metastatic LN stations. There was no significant difference in the number of retrieved LNs and the sensitivity for detecting metastatic LN stations between responders and non-responders.</div></div><div><h3>Conclusion</h3><div>Tumor response after chemotherapy did not influence the diagnostic performance of FL. The diagnostic performance of FL during gastrectomy following chemotherapy was acceptable. Similar to upfront surgery, FL can be safely applied even after chemotherapy.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 6","pages":"Article 109738"},"PeriodicalIF":3.5,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}